Use of smokeless tobacco and risk of cardiovascular disease: A systematic review and meta-analysis

European Journal of Preventive Cardiology

Volumn 23, Issue 18, 2016, Pages 1970-1981

  Vidyasagaran, Aishwarya L ^a   Siddiqi, Kamran ^a   Kanaan, Mona ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

cardiovascular disease; meta analysis; Smokeless tobacco; systematic review

Indexed keywords

BIBLIOGRAPHIC DATABASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; HEART DEATH; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SMOKELESS TOBACCO; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASE; FACTUAL DATABASE; GLOBAL HEALTH; RISK ASSESSMENT; RISK FACTOR; UTILIZATION;

CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; GLOBAL HEALTH; HUMANS; RISK ASSESSMENT; RISK FACTORS; TOBACCO, SMOKELESS;

EID: 84994512359     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487316654026     Document Type: Review

References (48)

1. Sinha DN, Palipudi KM, Rolle I, et al. Tobacco use among youth and adults in member countries of South-East Asia region: Review of findings from surveys under the Global Tobacco Surveillance System. Indian J Public Health 2011; 55: 169-176.
2. International Agency for Research on Cancer (IARC). Smokeless tobacco and some tobacco-specific N-nitrosamines. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon: IARC, 2008.
3. Kallischnigg G, Weitkunat R, Lee PN,. Systematic review of the relation between smokeless tobacco and non-neoplastic oral diseases in Europe and the United States. BMC Oral Health 2008; 8: 13-13.
4. Boffetta P, Hecht S, Gray N, et al. Smokeless tobacco and cancer. Lancet Oncol 2008; 9: 667-675.
5. Critchley JA, Unal B,. Health effects associated with smokeless tobacco: A systematic review. Thorax 2003; 58: 435-443.
6. Broadstock M. Systematic review of the health effects of modified smokeless tobacco products (NZTA Report), Vol. 10 (1). Christchurch: New Zealand Health Technology Assessment, 2007.
7. Mendis S, Puska P and Norrving B (Eds). Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization, 2011.
8. Boffetta P, Straif K,. Use of smokeless tobacco and risk of myocardial infarction and stroke: Systematic review with meta-analysis. Br Med J 2009 336.
9. Zhang L-N, Yang Y-M, Xu Z-R, et al. Chewing substances with or without tobacco and risk of cardiovascular disease in Asia: A meta-analysis. J Zhejiang Univ Sci B 2010; 11: 681-689.
10. Rahman MA, Mahmood MA, Spurrier N, et al. A systematic review of epidemiological studies on the association between smokeless tobacco use and coronary heart disease. J Public Health Epidemiol 2011; 3: 593-603.
11. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa (ON): Ottawa Health Research Institute, 2000.
12. Review Manager (RevMan). 5.3 ed. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
13. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009; 151: 264-269.
14. Hansson J, Pedersen NL, Galanti MR, et al. Use of snus and risk for cardiovascular disease: Results from the Swedish Twin Registry. J Intern Med 2009; 265: 717-724.
15. Hergens M-P, Ahlbom A, Andersson T, et al. Swedish moist snuff and myocardial infarction among men. Epidemiology 2005; 16: 12-16.
16. Hergens MP, Alfredsson L, Bolinder G, et al. Long-term use of Swedish moist snuff and the risk of myocardial infarction amongst men. J Intern Med 2007; 262: 351-359. Erratum appears in J Intern Med 2007; 262: 590.
17. Huhtasaari F, Asplund K, Lundberg V, et al. Tobacco and myocardial infarction: Is snuff less dangerous than cigarettes? Br Med J 1992; 305: 1252-1256.
18. Huhtasaari F, Lundberg V, Eliasson M, et al. Smokeless tobacco as a possible risk factor for myocardial infarction: A population-based study in middle-aged men. J Am Coll Cardiol 1999; 34: 1784-1790.
19. Johansson S-E, Sundquist K, Qvist J, et al. Smokeless tobacco and coronary heart disease: A 12-year follow-up study. Eur J Cardiovasc Prev Rehabil 2005; 12: 387-392. (Erratum appears in Eur J Cardiovasc Prev Rehabil 2007; 14: 722.).
20. Wennberg P, Eliasson M, Hallmans G, et al. The risk of myocardial infarction and sudden cardiac death amongst snuff users with or without a previous history of smoking. J Intern Med 2007; 262: 360-367.
21. Bolinder G, Alfredsson L, Englund A, et al. Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. Am J Public Health. 1994; 84: 399-404.
22. Asplund K, Nasic S, Janlert U, et al. Smokeless tobacco as a possible risk factor for stroke in men-A nested case-control study. Stroke 2003; 34: 1754-1759.
23. Hergens M-P, Lambe M, Pershagen G, et al. Smokeless tobacco and the risk of stroke. Epidemiology 2008; 19: 794-799. (Erratum appears in Epidemiology 2009; 20: 471).
24. Accortt NA, Waterbor JW, Beall C, et al. Chronic disease mortality in a cohort of smokeless tobacco users. Am J Epidemiol 2002; 156: 730-737.
25. Henley SJ, Thun MJ, Connell C, et al. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control 2005; 16: 347-358.
26. Rahman MA, Spurrier N, Mahmood MA, et al. Is there any association between use of smokeless tobacco products and coronary heart disease in Bangladesh? PLoS One 2012; 7: e30584-e30584.
27. Rahman MA, Zaman MM,. Smoking and smokeless tobacco consumption: Possible risk factors for coronary heart disease among young patients attending a tertiary care cardiac hospital in Bangladesh. Public Health 2008; 122: 1331-1338.
28. Mateen F, Carone M, Alam N, et al. A population-based case-control study of 1250 stroke deaths in rural Bangladesh. Eur J Neurol 2012; 19: 999-1006.
29. Gupta PC, Pednekar MS, Parkin D, et al. Tobacco associated mortality in Mumbai (Bombay) India. Results of the Bombay cohort study. Int J Epidemiol 2005; 34: 1395-1402.
30. Vendhan G, Vendhan K,. Tobacco chewing and adult mortality: A case-control analysis of 22,000 cases and 429,000 controls, never smoking tobacco and never drinking alcohol, in South India. Asian Pac J Cancer Prev 2015; 16: 1201-1206.
31. Alexander M. Tobacco use and the risk of cardiovascular diseases in developed and developing countries. PhD Thesis, University of Cambridge, 2013.
32. Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: A case-control study. Lancet 2006; 368: 647-658.
33. World Health Organization (WHO). The international statistical classification of diseases and health related problems ICD-10. Geneva: WHO, 2004.
34. Sinha DN, Suliankatchi RA, Gupta PC,. Smokeless tobacco (SLT) associated cancers: A systematic review and meta-analysis of Indian studies. Int J Cancer 2015; 138 (6): 1368-1379.
35. Stepanov I, Hecht SS, Ramakrishnan S, et al. Tobacco-specific nitrosamines in smokeless tobacco products marketed in India. Int J Cancer 2005; 116: 16-19.
36. Österdahl B-G, Jansson C, Paccou A,. Decreased levels of tobacco-specific N-nitrosamines in moist snuff on the Swedish market. J Agric Food Chem 2004; 52: 5085-5088.
37. Piano MR, Benowitz NL, FitzGerald GA, et al. Impact of smokeless tobacco products on cardiovascular disease: Implications for policy, prevention, and treatment a policy statement from the American Heart Association. Circulation 2010; 122: 1520-1544.
38. Guh J-Y, Chen H-C, Tsai J-F, et al. Betel-quid use is associated with heart disease in women. Am J Clin Nutr 2007; 85: 1229-1235.
39. Lin W-Y, Chiu T-Y, Lee L-T, et al. Betel nut chewing is associated with increased risk of cardiovascular disease and all-cause mortality in Taiwanese men. Am J Clin Nutr 2008; 87: 1204-1211.
40. Arain SS, Kazi TG, Arain JB, et al. Preconcentration of toxic elements in artificial saliva extract of different smokeless tobacco products by dual-cloud point extraction. Microchem J 2014; 112: 42-49.
41. McNeill A, Bedi R, Islam S, et al. Levels of toxins in oral tobacco products in the UK. Tob Control 2006; 15: 64-67.
42. Mahmarian JJ, Moyé LA, Nasser GA, et al. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol 1997; 30: 125-130.
43. Arefalk G, Hergens MP, Ingelsson E, et al. Smokeless tobacco (snus) and risk of heart failure: Results from two Swedish cohorts. Eur J Prev Cardiol 2012; 19: 1120-1127.
44. Haglund B, Eliasson M, Stenbeck M, et al. Is moist snuff use associated with excess risk of IHD or stroke? A longitudinal follow-up of snuff users in Sweden. Scand J Public Health 2007; 35: 618-622.
45. Hergens MP, Lambe M, Pershagen G, et al. Risk of hypertension amongst Swedish male snuff users: A prospective study. J Intern Med 2008; 264: 187-194.
46. Ronksley PE, Brien SE, Turner BJ, et al. Association of alcohol consumption with selected cardiovascular disease outcomes: A systematic review and meta-analysis. Br Med J 2011; 342: d671-d671.
47. Croucher R, Dahiya M, Gowda KK,. Contents and price of vendor assembled paan quid with tobacco in five London localities: A cross-sectional study. Tob Control 2013; 22: 141-143.
48. World Health Organization. Cardiovascular diseases (CVDs) fact sheet 317, http://www.who.int/mediacentre/factsheets/fs317/en/ (2015, accessed 15 February 2016).